Analysis
AI & Data
Plasma ctDNA and marrow NGF in myeloma
A 2026 myeloma study compared tumor-informed circulating DNA in plasma with marrow next-generation flow. Blood positivity may be informative while blood negativity frequently misses NGF-positive marrow disease.
Technical Review of peer-reviewed original longitudinal HemaSphere research. DOI 10.1002/hem3.70405. Editorial review only, not independent science or clinical validation.
Standfirst: A 2026 myeloma study compared tumor-informed circulating DNA in plasma with marrow next-generation flow. Blood positivity may be informative while blood negativity frequently misses NGF-positive marrow disease.
Not the same specimen, not the same measurand
Buenache and colleagues assessed myeloma residual disease in patients from PETHEMA/GEM trials. Tumor-informed sequencing in plasma required a trackable somatic variant established from diagnostic material. EuroFlow next-generation flow cytometry (NGF) assessed residual plasma cells in bone marrow. Molecular detection of blood tumor DNA and cellular detection of residual marrow plasma cells address different compartments and detection mechanisms.
Key observation: an asymmetric comparison
The team analysed 84 baseline patients and identified suitable monitoring variants in 77 (92%). From 292 serial plasma samples, 16 were ctDNA positive, representing nine patients. Yet among 29 marrow NGF-MRD-positive patients, only eight had positive plasma ctDNA (28%). Thus a negative plasma test does not establish marrow clearance. Eight of nine ctDNA-positive patients experienced progression in follow-up, a concerning signal from a small group rather than proof of universal prognostic accuracy.
Questions before transferring the method
Confirm baseline genotyping availability, cfDNA purity and amount, extraction workflow, plasma volume, intervals between marrow and blood collection, and each platform's analytical sensitivity. Different sampling schedules and spatial heterogeneity can explain discordance. Observational comparisons of progression are not a direct comparison of analytical LoD or a substitute for full NGF assay validation.

Daily Learning Pill
In this cohort, plasma ctDNA was undetectable in 21 of 29 patients with detectable marrow MRD by NGF.
Read the original study. More methods guidance: CFCM Resources.